TipRanks
Go Ultimate55% OFF

Compare ALK-abello (4AJ0) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:4AJ0ALK-abelloEUR 33.42EUR 7.39B40.6617.93%―Unlock the DE:4AJ0 analyst price target with TipRanks PremiumDE:4AJ0Unlock the DE:4AJ0 top-analyst price target with TipRanks Premium
AKBLFALK-abello$37.23$8.25B40.6614.03%―Unlock the AKBLF analyst price target with TipRanks PremiumDE:4AJ0 vs AKBLFUnlock the AKBLF top-analyst price target with TipRanks Premium
INOInovio Pharmaceuticals$1.76$62.29M-0.52-74.49%Strong BuyUnlock the INO analyst price target with TipRanks PremiumDE:4AJ0 vs INOUnlock the INO top-analyst price target with TipRanks Premium
ACRSAclaris Therapeutics$3.86$584.38M-6.8459.44%Strong BuyUnlock the ACRS analyst price target with TipRanks PremiumDE:4AJ0 vs ACRSUnlock the ACRS top-analyst price target with TipRanks Premium
EBSEmergent Biosolutions$6.74$349.17M-1.98-46.96%NeutralUnlock the EBS analyst price target with TipRanks PremiumDE:4AJ0 vs EBSUnlock the EBS top-analyst price target with TipRanks Premium
NVSNovartis$160.58$296.91B31.1931.14%Moderate BuyUnlock the NVS analyst price target with TipRanks PremiumDE:4AJ0 vs NVSUnlock the NVS top-analyst price target with TipRanks Premium
BMYBristol-Myers Squibb$62.57$127.71B13.8236.96%Moderate BuyUnlock the BMY analyst price target with TipRanks PremiumDE:4AJ0 vs BMYUnlock the BMY top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:4AJ0ALK-abello33.425.0617.84%
AKBLFALK-abello37.234.8515.00%
INOInovio Pharmaceuticals0.60-1.90-75.92%
ACRSAclaris Therapeutics3.971.4155.08%
EBSEmergent Biosolutions6.81-3.68-35.08%
NVSNovartis160.7939.3132.36%
BMYBristol-Myers Squibb62.4818.4241.81%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts